

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



April 13, 2018

### Pharmacy Benefit Exclusion for Crysvida® (burosumab)

Crysvida® (burosumab) is a new drug product anticipated to be approved for X-Linked Hypophosphatemia (XLH). Crysvida® (burosumab) is expected to be approved on or before April 18, 2018. Upon launch, Crysvida® (burosumab) will be excluded from pharmacy benefit coverage due to Crysvida® (burosumab) clinician-administered route of administration. Crysvida® (burosumab) may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Crysvida® (burosumab)

### Products Impacted

This notice applies to commercial lines of business **and** the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)
- SecureBlue (MSHO)

### Products Not Impacted

Federal Employee Program, Platinum Blue and Medicare Supplement subscribers are not impacted.

### Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.